RBC Capital analyst Ashish Sabadra raised the firm’s price target on CME Group (CME) to $282 from $269 and keeps a Sector Perform rating on the shares. Near-term market dynamics supported solid volume growth in Q2, while Market and Data Information continues to benefit from increased subscriber growth and pricing tailwinds, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CME:
- CME Group price target lowered to $303 from $304 at Morgan Stanley
- CME Group downgraded to Neutral from Buy at UBS
- CME Group price target raised to $303 from $300 at Oppenheimer
- Positive Outlook for CME Group Driven by Risk Management Demand and Strong Financial Position
- CME Group price target lowered to $298 from $299 at Barclays